Strategic sequencing of bladder-sparing therapies in the management of BCG-unresponsive non-muscle invasive bladder cancer

🧪Our new editorial on BCG‑unresponsive NMIBC makes a simple point: therapies are expanding, but we still lack an evidence‑based sequencing roadmap. Until trials and biomarkers arrive, patient‑centered decision‑making is the only honest approach. https:/…